Aptar Digital Health has partnered with AstraZeneca to develop AI-powered algorithms for detecting cardiovascular, renal, and metabolic conditions like chronic kidney disease (CKD).
The collaboration aims to leverage AstraZeneca’s AI-driven screening algorithms to accelerate CKD detection during eye examinations.
AstraZeneca initiated the development of the algorithms based on thousands of biomarkers and diagnosis data points, showing promising results in early CKD detection.
Ophthalmologists can use advanced algorithms during fundus imaging examinations to identify early CKD signs, similar to diabetes screening.
AstraZeneca cardiovascular, renal and metabolism senior vice president Mina Makar said: “Chronic kidney disease remains one of the most significant global health challenges, with persistently low diagnosis rates.
The partnership with Aptar represents an exciting opportunity to drive innovation in chronic kidney disease management and our commitment to enhance diagnostics in novel ways.
“We are collaborating at scale to deliver sustainable solutions for millions of people living with chronic kidney disease worldwide.”
Aptar Digital Health, part of AptarGroup, offers a range of digital health solutions, including mobile apps, connected drug delivery systems, and advanced data analysis services.
The partnership highlights Aptar Digital Health’s expertise in creating scalable digital health solutions through AI and data science, supporting the healthcare community.
Upon completion, the solution will undergo clinical evaluation for market access and deployment with stakeholders, including pharmaceutical companies and care systems.
Aptar Digital Health president Romain Marmot said: “With early detection and timely treatment, patients are likely to experience better health outcomes.
“The collaboration aims to enhance the overall quality of care for patients with CKD by providing an innovative and effective early detection tool.”
Aptar Pharma president Gael Touya said: “We are delighted to collaborate with AstraZeneca to progress the development and deployment of an innovative and non-intrusive method to help with earlier identification of CKD.
“This collaboration enables Aptar Digital Health to broaden its scope in the field of biomarkers and digital diagnostics, opening up new opportunities to harness digital health technology to detect diseases earlier and accelerate identification of individuals in need of care.”
